CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 120 filers reported holding CYMABAY THERAPEUTICS INC in Q2 2018. The put-call ratio across all filers is 0.78 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2023 | $3,778 | +123.3% | 159,950 | +41.0% | 0.01% | +100.0% |
Q3 2023 | $1,692 | -42.8% | 113,450 | -58.0% | 0.00% | -25.0% |
Q2 2023 | $2,957 | -29.6% | 270,020 | -43.9% | 0.00% | -33.3% |
Q1 2023 | $4,199 | +32.4% | 481,500 | -4.8% | 0.01% | +50.0% |
Q4 2022 | $3,172 | -99.8% | 505,900 | +3.1% | 0.00% | +100.0% |
Q3 2022 | $1,718,000 | +13.2% | 490,800 | -4.6% | 0.00% | 0.0% |
Q2 2022 | $1,518,000 | +6.2% | 514,620 | +12.0% | 0.00% | 0.0% |
Q1 2022 | $1,429,000 | +96.0% | 459,535 | +113.1% | 0.00% | +100.0% |
Q4 2021 | $729,000 | -61.0% | 215,620 | -57.9% | 0.00% | -50.0% |
Q3 2021 | $1,871,000 | -46.1% | 512,591 | -35.6% | 0.00% | -50.0% |
Q2 2021 | $3,472,000 | -14.1% | 796,220 | -10.6% | 0.00% | -20.0% |
Q1 2021 | $4,041,000 | +71.8% | 890,163 | +117.3% | 0.01% | +66.7% |
Q4 2020 | $2,352,000 | +104.3% | 409,720 | +157.8% | 0.00% | +200.0% |
Q3 2020 | $1,151,000 | +272.5% | 158,920 | +79.5% | 0.00% | – |
Q2 2020 | $309,000 | -62.9% | 88,520 | -79.2% | 0.00% | -100.0% |
Q4 2019 | $833,000 | +308.3% | 424,840 | +964.2% | 0.00% | – |
Q3 2019 | $204,000 | -88.3% | 39,920 | -70.3% | 0.00% | -100.0% |
Q2 2018 | $1,747,000 | 0.0% | 134,500 | 0.0% | 0.00% | -50.0% |
Q1 2018 | $1,747,000 | -2.2% | 134,500 | -30.7% | 0.00% | 0.0% |
Q4 2017 | $1,786,000 | -61.1% | 194,100 | -66.0% | 0.00% | -60.0% |
Q3 2017 | $4,596,000 | +154.6% | 570,200 | +81.9% | 0.01% | +150.0% |
Q2 2017 | $1,805,000 | +81.0% | 313,392 | +35.1% | 0.00% | +100.0% |
Q1 2017 | $997,000 | +391.1% | 231,949 | +97.6% | 0.00% | – |
Q4 2016 | $203,000 | -13.2% | 117,400 | -2.8% | 0.00% | – |
Q3 2016 | $234,000 | +4.9% | 120,800 | -5.8% | 0.00% | – |
Q2 2016 | $223,000 | +48.7% | 128,300 | +15.6% | 0.00% | – |
Q1 2016 | $150,000 | +45.6% | 111,000 | +82.3% | 0.00% | – |
Q4 2015 | $103,000 | – | 60,900 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Foresite Capital Management IV, LLC | 1,787,094 | $26,645,572 | 14.80% |
Lynx1 Capital Management LP | 994,161 | $14,822,941 | 9.80% |
Octagon Capital Advisors LP | 3,073,750 | $45,829,613 | 7.04% |
Saturn V Capital Management LP | 1,124,459 | $16,765,684 | 7.02% |
Altium Capital Management LP | 800,000 | $11,928,000 | 6.22% |
Affinity Asset Advisors, LLC | 1,129,376 | $16,838,996 | 4.74% |
ACUTA CAPITAL PARTNERS, LLC | 418,000 | $6,232,380 | 4.18% |
Cormorant Asset Management, LP | 3,850,000 | $57,403,500 | 3.35% |
SILVERARC CAPITAL MANAGEMENT, LLC | 590,000 | $8,796,900 | 2.67% |
MPM BioImpact LLC | 610,770 | $9,106,581 | 2.43% |